Company intelligence / Profile preview

Illumacell

Waterloo, Ontario, Canadaillumacell.com ↗

Ownership: Private
Development stage: Phase 1

Overview

“The Illumacell photodynamic treatment of mice with a subcutaneous malignant breast cancer resulted in a dramatic reduction of the size or outright elimination of the tumor. On histological analysis a remarkable inflammatory response coincided with the reduction or elimination of the tumor. The data from the pathological analysis indicate that the Illumacell treatment is responsible for mounting a remarkable and effective inflammatory response... that can result in complete elimination of the malignant tumor.”

Therapeutic areas: Oncology
Modalities: Photodynamic therapy (PDT)medical devices
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

5-aminolevulinic acid

Phase 1

Indications: Cancer, Chronic foot ulcers

Beyond the preview

Go deeper on Illumacell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Illumacell.

Explore the full profile